Recombinant expression plasmid and application thereof in preparing anti-tumor immunogene therapeutic medicament

A technology of anti-tumor immunity and expressing plasmids, applied in the field of biopharmaceuticals
CN102776235AInactive Publication Date: 2012-11-14INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
2 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Publication Date
2012-11-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an anti-tumor immunogene therapeutic medicament capable of activating the immunoreaction of the organism and having anti-tumor effect. The active ingredient of the anti-tumor immunogene therapeutic medicament is pVAX-IL-12-GB; three immunoregulation factor genes of human IL-12, GM-CSF and B7.1 are cloned to the same plasmid DNA vector pVAX1, and co-expression of upstream and downstream genes is realized through an internal ribosome entry site (IRES); and the vector is imported into a host so that the human immunoregulation factors IL-12, GM-CSF and B7.1 can be expressed simultaneously. The invention provides a novel anti-tumor immunogene therapeutic agent, wherein a plurality of anti-tumor immunoregulation factors are combined for use so that mutual costimulation of the factors can be developed and the organism can be better induced to produce anti-tumor immunoreaction; and therefore, the anti-tumor immunogene therapeutic medicament lays a firm foundation for further developing tumor immunogene treatment study and is wide in application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention belongs to a gene medicine in the field of biopharmaceuticals, and particularly relates to an anti-tumor immune gene therapy drug that can activate the body's immune response and has an anti-tumor effect. Background technique

[0002] In addition to the characteristic low expression of major histocompatibility antigens and costimulatory molecules such as B7.1 and CD86, the immune tolerance of malignant tumors is also closely related to the microenvironment of the tumor. There are a large number of immunosuppressive cytokines such as IL-10 and tumor growth factor β in the tumor microenvironment. It is through the regulation of the cytokine network in the microenvironment that tumor cells escape the anti-tumor immune response (Coussens LM, Werb Z. and Cancer[J].Nature,2002,420(6917):860-7;6abrilovich D.Mechanisms and functional significance of tumour-induced dendritic-cell defects[J].Nat Rev Immunol,2004,4(12):941 -52.). Therefore, the cytokin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More